These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17464097)

  • 21. Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2.
    Yang S; Fang Z; Gurates B; Tamura M; Miller J; Ferrer K; Bulun SE
    Mol Endocrinol; 2001 Dec; 15(12):2093-105. PubMed ID: 11731611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
    Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
    J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
    Utsunomiya H; Suzuki T; Kaneko C; Takeyama J; Nakamura J; Kimura K; Yoshihama M; Harada N; Ito K; Konno R; Sato S; Okamura K; Sasano H
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3436-43. PubMed ID: 11443221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.
    Deli T; Orosz M; Jakab A
    Pathol Oncol Res; 2020 Jan; 26(1):63-78. PubMed ID: 30617760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy.
    Gompel A
    Climacteric; 2018 Aug; 21(4):321-325. PubMed ID: 29583028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer.
    Smuc T; Rizner TL
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):74-82. PubMed ID: 18930784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters.
    Han B; Li S; Song D; Poisson-Paré D; Liu G; Luu-The V; Ouellet J; Li S; Labrie F; Pelletier G
    J Steroid Biochem Mol Biol; 2008 Dec; 112(4-5):194-200. PubMed ID: 18996480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progestins and cancer.
    Sitruk-Ware R; Plu-Bureau G
    Gynecol Endocrinol; 1999 Jun; 13 Suppl 4():3-9. PubMed ID: 12227896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 17beta-hydroxysteroid dehydrogenases in human breast cancer.
    Nagasaki S; Miki Y; Akahira J; Suzuki T; Sasano H
    Ann N Y Acad Sci; 2009 Feb; 1155():25-32. PubMed ID: 19250189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2009 Dec; 25(12):807-15. PubMed ID: 19906000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progestins and breast cancer.
    Eden J
    Am J Obstet Gynecol; 2003 May; 188(5):1123-31. PubMed ID: 12748456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are progestins really necessary as part of a combined HRT regimen?
    Sturdee DW
    Climacteric; 2013 Aug; 16 Suppl 1():79-84. PubMed ID: 23651281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone replacement therapy and endometrial cancer.
    Emons G; Huschmand-Nia A; Krauss T; Hinney B
    Onkologie; 2004 Apr; 27(2):207-10. PubMed ID: 15138357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo and in vitro estrogenic and progestagenic actions of Tibolone.
    Sadarangani A; Salgado AM; Kato S; Pinto M; Carvajal A; Monso C; Owen GI; Vigil P
    Biol Res; 2005; 38(2-3):245-58. PubMed ID: 16238103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
    Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
    Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of endometrial cancer following estrogen replacement with and without progestins.
    Weiderpass E; Adami HO; Baron JA; Magnusson C; Bergström R; Lindgren A; Correia N; Persson I
    J Natl Cancer Inst; 1999 Jul; 91(13):1131-7. PubMed ID: 10393721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.